Patient-reported Outcomes After External Beam Radiotherapy With Low Dose Rate Brachytherapy Boost vs Radical Prostatectomy for Localized Prostate Cancer: Five-year Results From a Prospective Comparative Effectiveness Study

Purpose: Data comparing radical prostatectomy and external beam radiation therapy with low dose rate brachytherapy boost are lacking. To better guide shared decision making regarding treatment, we compared patient reported outcomes through 5 years following radical prostatectomy or external beam radiation therapy with low dose rate brachytherapy boost for localized prostate cancer. Materials and Methods: From 2011-2012, men aged <80 years with localized prostate adenocarcinoma were enrolled and followed longitudinally. Patient reported outcomes included the Expanded Prostate Index Composite. Regression models adjusted for baseline scores and covariates were constructed. Results: The study population included 112 men treated with external beam radiation therapy with low dose rate brachytherapy boost and 1,553 treated with radical prostatectomy. Compared to radical prostatectomy, external beam radiation therapy with low dose rate brachytherapy boost was associated with clinically meaningful worse urinary irritative/obstructive (adjusted mean score difference [95% confidence interval]: 5.0 [−8.7, −1.3]; P = .008 at 5 years) and better urinary incontinence function (13.3 [7.7, 18.9]; P < .001 at 5 years) through 5 years. Urinary function bother was similar between groups (P > .4 at all timepoints). Treatment with external beam radiation therapy with low dose rate brachytherapy boost was associated with worse bowel function (−4.0 [−6.9, −1.1]; P = .006 at 5 years) through 5 years compared to radical prostatectomy. Treatment with external beam radiation therapy with low dose rate brachytherapy boost was associated with better sexual function at 1 year (12.0 [6.5, 17.5]; P < .001 at 1 year) compared to radical prostatectomy, but there was insufficient evidence to reject the supposition that no difference was seen at 3 or 5 years. Conclusions: Compared to radical prostatectomy, external beam radiation therapy with low dose rate brachytherapy boost was associated with clinically meaningful worse urinary irritative/obstructive and bowel functions but better urinary incontinence function through 5 years after treatment. These patient-reported functional outcomes may clarify treatment expectations and help inform treatment choices for localized prostate cancer.

[1]  É. Vigneault,et al.  PSA outcomes and late toxicity of single-fraction HDR brachytherapy and LDR brachytherapy as monotherapy in localized prostate cancer: A phase 2 randomized pilot study. , 2021, Brachytherapy.

[2]  N. Clarke,et al.  Patient-reported functional outcomes following external beam radiation therapy for prostate cancer with and without a high-dose rate brachytherapy boost: a national population-based study. , 2020, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[3]  M. Cooperberg,et al.  Patient-Reported Outcomes Through 5 Years for Active Surveillance, Surgery, Brachytherapy, or External Beam Radiation With or Without Androgen Deprivation Therapy for Localized Prostate Cancer. , 2020, JAMA.

[4]  A. D'Amico,et al.  Combined External Beam Radiation Therapy and Brachytherapy Versus Radical Prostatectomy with Adjuvant Radiation Therapy for Gleason 9-10 Prostate Cancer , 2019, International Journal of Radiation Oncology*Biology*Physics.

[5]  A. D'Amico,et al.  Surgery vs Radiotherapy in the Management of Biopsy Gleason Score 9-10 Prostate Cancer and the Risk of Mortality , 2019, JAMA oncology.

[6]  D. Brachman,et al.  Patient Reported Outcomes of NRG Oncology/RTOG 0232: A Phase III Study Comparing Combined External Beam Radiation and Transperineal Interstitial Permanent Brachytherapy with Brachytherapy Alone in Intermediate Risk Prostate Cancer , 2018, International Journal of Radiation Oncology*Biology*Physics.

[7]  A. Kishan,et al.  Radical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy With Brachytherapy Boost and Disease Progression and Mortality in Patients With Gleason Score 9-10 Prostate Cancer , 2018, JAMA.

[8]  J. Tward,et al.  Factors influencing prostate cancer patterns of care: An analysis of treatment variation using the SEER database , 2018, Advances in radiation oncology.

[9]  W. J. Morris,et al.  ASCENDE-RT: An Analysis of Health-Related Quality of Life for a Randomized Trial Comparing Low-Dose-Rate Brachytherapy Boost With Dose-Escalated External Beam Boost for High- and Intermediate-Risk Prostate Cancer. , 2017, International Journal of Radiation Oncology, Biology, Physics.

[10]  W. J. Morris,et al.  Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): An Analysis of Survival Endpoints for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost to a Dose-Escalated External Beam Boost for High- and Intermediate-risk Prostate Cance , 2017, International journal of radiation oncology, biology, physics.

[11]  A. Kishan,et al.  Clinical Outcomes for Patients with Gleason Score 9-10 Prostate Adenocarcinoma Treated With Radiotherapy or Radical Prostatectomy: A Multi-institutional Comparative Analysis. , 2017, European urology.

[12]  Ronald C. Chen,et al.  Association Between Choice of Radical Prostatectomy, External Beam Radiotherapy, Brachytherapy, or Active Surveillance and Patient-Reported Quality of Life Among Men With Localized Prostate Cancer , 2017, JAMA.

[13]  David Gillatt,et al.  Patient-Reported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. , 2016, The New England journal of medicine.

[14]  James E. Helmreich Regression Modeling Strategies with Applications to Linear Models, Logistic and Ordinal Regression and Survival Analysis (2nd Edition) , 2016 .

[15]  U. Isacsson,et al.  Radical prostatectomy versus high-dose irradiation in localized/locally advanced prostate cancer: A Swedish multicenter randomized trial with patient-reported outcomes , 2015, Acta oncologica.

[16]  Roma Maguire,et al.  What is the value of the routine use of patient-reported outcome measures toward improvement of patient outcomes, processes of care, and health service outcomes in cancer care? A systematic review of controlled trials. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  A. Wein,et al.  Comparison of distribution- and anchor-based approaches to infer changes in health-related quality of life of prostate cancer survivors. , 2012, Health services research.

[18]  Martin G Sanda,et al.  Development and validation of an abbreviated version of the expanded prostate cancer index composite instrument for measuring health-related quality of life among prostate cancer survivors. , 2010, Urology.

[19]  S. Kaplan,et al.  Who Can Respond to Treatment?: Identifying Patient Characteristics Related to Heterogeneity of Treatment Effects , 2010, Medical care.

[20]  Wadih Arap,et al.  Quality of life and satisfaction with outcome among prostate-cancer survivors. , 2008, The New England journal of medicine.

[21]  D. Lubeck,et al.  Assessment of prognosis with the total illness burden index for prostate cancer , 2007, Cancer.

[22]  John T. Wei,et al.  Long-term outcomes among localized prostate cancer survivors: health-related quality-of-life changes after radical prostatectomy, external radiation, and brachytherapy. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  B. Bokhour,et al.  Measuring Patients' Perceptions of the Outcomes of Treatment for Early Prostate Cancer , 2003, Medical care.

[24]  D. Lubeck,et al.  The CaPSURE database: a methodology for clinical practice and research in prostate cancer. CaPSURE Research Panel. Cancer of the Prostate Strategic Urologic Research Endeavor. , 1996, Urology.

[25]  Barbara Gandek,et al.  Patient and Visit Characteristics Related to Physicians' Participatory Decision-Making Style: Results from the Medical Outcomes Study , 1995, Medical care.

[26]  D L Patrick,et al.  Screening for depression in well older adults: evaluation of a short form of the CES-D (Center for Epidemiologic Studies Depression Scale). , 1994, American journal of preventive medicine.

[27]  H. White A Heteroskedasticity-Consistent Covariance Matrix Estimator and a Direct Test for Heteroskedasticity , 1980 .

[28]  John T. Wei,et al.  Minimally important difference for the Expanded Prostate Cancer Index Composite Short Form. , 2015, Urology.

[29]  G. Andriole Long-Term Functional Outcomes after Treatment for Localized Prostate Cancer , 2013 .

[30]  Ware J.E.Jr.,et al.  THE MOS 36- ITEM SHORT FORM HEALTH SURVEY (SF- 36) CONCEPTUAL FRAMEWORK AND ITEM SELECTION , 1992 .

[31]  C. Sherbourne,et al.  The MOS social support survey. , 1991, Social science & medicine.

[32]  P. J. Huber The behavior of maximum likelihood estimates under nonstandard conditions , 1967 .